Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Operating Margin (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Operating Margin for 3 consecutive years, with 205.18% as the latest value for Q1 2025.

  • On a quarterly basis, Operating Margin changed N/A to 205.18% in Q1 2025 year-over-year; TTM through Sep 2025 was 1425.33%, a 771533.0% decrease, with the full-year FY2023 number at 2499.39%, changed N/A from a year prior.
  • Operating Margin was 205.18% for Q1 2025 at Centessa Pharmaceuticals, down from 1368.79% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 4138.78% in Q2 2022 to a low of 205.18% in Q1 2025.
  • A 3-year average of 2097.37% and a median of 1919.14% in 2023 define the central range for Operating Margin.
  • Biggest YoY gain for Operating Margin was -52053bps in 2023; the steepest drop was -221964bps in 2023.
  • Centessa Pharmaceuticals' Operating Margin stood at 1889.33% in 2022, then decreased by -28bps to 1368.79% in 2023, then tumbled by -115bps to 205.18% in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Operating Margin are 205.18% (Q1 2025), 1368.79% (Q4 2023), and 1582.41% (Q3 2023).